Half-Year Report for Six Months Ended 31 Dec 2025

AI SummaryClose X

Sareum Holdings PLC reported its unaudited half-year results for the six months ended 31 December 2025, with a loss before tax of £1.9 million and cash reserves of £2.5 million. The company has restarted the Phase 2-enabling toxicology programme for its lead autoimmune disease candidate, SDC-1801, following positive Phase 1 data and a sufficient cash runway. Preparations are underway to partner SDC-1802, a cancer immunotherapy asset, and SRA737, a cancer drug, with improved licensing terms for SRA737 securing 63.5% of future revenues. The company is also progressing a TYK2 neuroscience discovery programme and has engaged a business development consultancy to accelerate partnering discussions for SDC-1801 and SRA737.

Disclaimer*

UK 100

Latest directors dealings